QuidelOrtho Reports Q1 2026 Earnings Amid Weaker Respiratory Season
QuidelOrtho (QDEL) reported Q1 2026 earnings impacted by a weaker respiratory season, with influenza-like illness visits down 30% compared to the previous year. Total revenue was $620 million, with non-respiratory revenue at $552 million and respiratory revenue at $68 million. The company also noted a 8% decline in labs business revenue due to the milder respiratory season and the end of a joint business agreement with Grifols.
Tickers: $QDEL
Topics: cash flow earnings market conditions respiratory season revenue decline